Polycystic ovary syndrome: not ovarian, not simple, unkind
Abstract
Polycystic ovary syndrome is one of the most common endocrinopathies worldwide and for many years it was one of the most difficult to elucidate. In the last 10 years, understanding of this condition has increased greatly. It is now clear that polycystic ovary syndrome is not an ovarian disease, rather it is a disorder of intermediary metabolism characterized by insulin resistance. It has also become clear that insulin resistance has implications for general well-being and for the development of novel treatments.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.